Name: Susan Solomon: 幹細胞研究所承諾的未來
Uploaded: 2012-09-13T15:16:16Z
Duration: 14 min 41 s
Description: 蘇珊·所羅門 將幹細胞稱作身體內的修補工具, 並且主張利用實驗室]產製的幹細胞系列進行研究. 他的團隊發展出 培育多功能幹細胞系列的方法, 建構了可以加速藥物研發的測試平台, 可能帶動未來個人化製義與治療的發展, 不僅僅是針對特定的疾病, 而且還能針對特定的個人.

Embryonic stem cell lines derived from human blastocysts

Induction of pluripotent stem cells from adult human fibroblasts by defined factors

The Truly Staggering Cost of Inventing New Drugs

Vioxx's history and the need for better procedures and better testing

蘇珊·所羅門 將幹細胞稱作身體內的修補工具, 並且主張利用實驗室]產製的幹細胞系列進行研究. 他的團隊發展出 培育多功能幹細胞系列的方法, 建構了可以加速藥物研發的測試平台, 可能帶動未來個人化製義與治療的發展, 不僅僅是針對特定的疾病, 而且還能針對特定的個人.

Susan Solomon: 幹細胞研究所承諾的未來

Lab-grown stem cells are transforming disease research and drug development, moving medicine beyond a one-size-fits-all approach. Scientists can now create thousands of genetically diverse stem cell avatars, allowing for 'clinical trials in a dish' using real human cells. This breakthrough could slash the average 13-year, $4 billion cost of bringing a single drug to market. By modeling diseases in human cells, researchers gain an unprecedented window into both illness and potential cures.